News
Monday 22 December 2014
The National Institute for Health and Care Excellence (NICE) have today published the draft guidance on their recent Multiple Technology Appraisal of certain ovarian cancer drugs. The NICE committee has been consulting on a review of the use of topotecan (Hycamtin), pegylated liposomal doxorubicin...
News
Friday 19 December 2014
You may have read or heard the news that the drug olaparib (to be marketed as Lynparza) has been approved by the European Commission, to be used by women with platinum-sensitive relapsed BRCA1 or BRCA2 mutated high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who...
Blog
Wednesday 17 December 2014
Last month I was lucky enough to join our Research Advocates on a fascinating visit to the University of Nottingham. There we met the enthusiastic Dr Srinivasan Madhusudan and his colleague Dr Rachel Doherty who are conducting research into potential ways to increase the effectiveness of...
Blog
Wednesday 10 December 2014
The 16th annual Britain Against Cancer conference took place yesterday. Target Ovarian Cancer staff members and advocates attended the conference, and also had an exhibition stand to raise awareness of our work with delegates. The stand was very well received with a steady flow of delegates...

Pages